CMPXCompass Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 13539
Ticker: CMPX
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2020-11-13
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: CMPX

Detail

Enriched 2026-08-14 20:47

Market cap: $426,808,358.55
Shares outstanding (class): 180,087,915
Shares outstanding (weighted): 180,087,915
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 39
Location: BOSTON, MA
Homepage: https://www.compasstherapeutics.com
Description: Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Market cap and share counts drift.

Funds holding this security

80 funds · 82 positions · $98.47M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$22.17M	0.00%	4,190,854 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$19.49M	0.26%	3,684,989 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$16.73M	0.02%	3,162,746 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$9.05M	0.01%	1,710,944 NS	FIGI
ROYCE SMALL-CAP TRUST, INC. —	—	$3.05M	0.14%	576,468 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$3.02M	0.02%	571,013 NS	FIGI
iShares Russell 2000 Value ETF iShares Trust	IWN	$2.76M	0.02%	522,428 NS	FIGI
Royce Small-Cap Fund ROYCE FUND	—	$2.60M	0.14%	490,597 NS	FIGI
JPMorgan Small Cap Value Fund JPMorgan Trust II	—	$1.83M	0.16%	345,308 NS	FIGI
ROYCE MICRO-CAP TRUST, INC. —	—	$1.77M	0.26%	334,649 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$1.72M	0.14%	325,074 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$1.26M	0.00%	237,419 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$1.17M	0.02%	221,492 NS	FIGI
Meridian Small Cap Growth Fund Meridian Fund Inc	—	$1.12M	0.48%	211,802 NS	FIGI
Royce Micro-Cap Fund ROYCE FUND	—	$822.8K	0.26%	155,547 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERCMPX
FIGI_COMPOSITEBBG00LPXKF25
FIGI_SHARE_CLASSBBG00LPXKF34
CIK0001738021
ISINUS20454B1044
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapies, fitting the biotechnology industry under healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.